Agitation in Biological Technology

Alexza Reports 2008 First Quarter Financial Results and Updates Development of Product Candidates

... developing AZ-004 for the treatment of acute agitation in patients with schizophrenia or bipolar ... 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial is ... dose. Various assessments of a patient's agitation state will be conducted at serial time points ...

Alexza Initiates First Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)

... being developed for the treatment of acute agitation in patients with schizophrenia or bipolar ... 300 schizophrenic patients with acute agitation at 25 U.S. clinical centers. The trial is an ... first dose. Various assessments of a patient's agitation state will be conducted at serial time points ...

Alexza Consolidates Operations to Focus Resources on AZ-004 (Staccato(R) Loxapine) for Acute Agitation

... which is in late-stage clinical development for the acute treatment of agitation in patients with schizophrenia or bipolar disorder. The Company has ... (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and ...

Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009

... ease, patient comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, ...

Alexza's Corporate Presentation to be Webcast at the Future Leaders in the Biotech Industry Conference

... ease, patient comfort and convenience. Alexza's lead program is AZ-004 ( Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, ...

Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference

... ease, patient comfort and convenience. Alexza's lead program is AZ-004 (Staccato loxapine) and is being developed for the acute treatment of agitation in schizophrenic or bipolar disorder patients. Alexza has completed and announced positive results from both of its AZ-004 Phase 3 clinical trials, ...

Alexza Pharmaceuticals Announces Upcoming Webcasts and Conference Participation

... Alexza has five product candidates in active clinical development. Alexza's lead program, AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic or bipolar disorder patients, is in Phase 3 testing and has completed enrollment of its first Phase 3 clinical trial. A second Phase ...

Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering

... of clinical product candidates. Alexza's lead program, AZ-004 (Staccato(R) loxapine) is in Phase 3 clinical testing for the treatment of acute agitation in schizophrenic or bipolar disorder patients. Mr. Kurtz was most recently Vice President of Research and Development and Director, Pharmaceutical ...

Sentry Enhances Offerings with Temperature-Controlled Custom Bio-Pharmaceutical Finishing Services

... -- Packaging: Sentry provides custom and pre-qualified packaging (external and internal) solutions that mitigate transport impact and agitation risk. Temperature-specific work zones reduce or eliminate product time-out-of temperature. -- Kitting: Offering can reduce freight and ...

ExonHit Therapeutics - 2007 Financial Results

... commented: "We have reached our main objectives in 2007. We are very proud of the work accomplished by our collaborators in a context of market agitation which has been very disturbing for companies like ExonHit which invest in innovation with 65% of its operating expenses devoted to R&D. We have ...

FDA Approves PRISTIQ(TM) for the Treatment of Adult Patients with Major Depressive Disorder

... loss of interest or pleasure: depressed mood; loss of interest or pleasure; changes in appetite or weight; changes in sleeping patterns; psychomotor agitation or retardation; fatigue or low energy; feeling worthless or guilty for no reason; difficulty thinking or concentrating; or thoughts of death or ...

Alexza's Corporate Presentation to be Webcast at the 10th Annual BIO CEO & Investor Conference

... ease, patient comfort and convenience. Alexza has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-104 (Staccato ...

Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference to Webcast Alexza's Corporate Presentation

... ease, patient comfort and convenience. Alexza has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-104 (Staccato ...

Alexza Announces Partnership With Endo for AZ-003 (Staccato(R) fentanyl) in North America

... ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato ...

Alexza Elects Dr. Hal V. Barron to Its Board of Directors

... ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato ...

19th Annual Piper Jaffray Health Care Conference to Webcast Alexza's Corporate Presentation

... ease, patient comfort and convenience. The Company has six product candidates in development; AZ-004 (Staccato loxapine) for the treatment of acute agitation in schizophrenic and bipolar disorder patients, AZ-001 (Staccato prochlorperazine) for the acute treatment of migraine headaches, AZ-002 (Staccato ...

Fundamentals of Fermentation: Techniques For Benchtop Fermentors

... protein secreted by the microorganism, agitation speed, and other factors. Therefore, you will ... CONTROL SETTINGS, (i.e. temp., pH, agitation speed, D.O. & gas sparge rate)? ... yeast the values are 300C and a pH value of 5.0. agitation speed is usually set to a minimum of ...

Scaling-Up from Spinners, T-Flasks & Shakers: A versatile bioreactor for mammalian and microbial cells

... shear forces exerted by contact with gas bubbles. agitation rates in microbial fermentors are often set to ... shear-sensitive and can not survive high agitation rates ( Figure 2 ). agitation in mammalian culture rarely exceeds 150 rpm. ...

Hybridoma Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor

... vessel assembly including a pitched blade agitation impeller, foam/level sensors, as well as ... items. Optional direct drive and magnetic-drive agitation systems, as well heat-blanketed vessel options, ... . . . . . . . . . . . . . . . . .. .50% agitation . . . . . . . . . . . . . . . . .. .70-130 rpm ...

E. coli Fermentation Using a BioFlo 110 Bench-Top Fermentor

... . . . . . . . . . . . . . . . .35% agitation . . . . . . . . . . . . . . . . . . . . .. .. ...... cable), and at 100%, (obtained using 1,200 rpm agitation and 5L/M [1 vvm] airflow). After calibration, ... 100% until inoculation. An agitation cascade was selected in the controller ...

CHO Cell Culture Application Using a BioFlo 110 Benchtop Bioreactor

... vessel assembly including a pitched blade agitation impeller, foam/level sensors, as well as ... with choice of direct drive or magnetic-drive agitation systems, as well choice of water-jacketed or ... . . . . . . . . . . . . . . . . .50% agitation . . . . . . . . . . . . . . . . . . .70-130 rpm ...

P. pastoris Fermentation using a BioFlo 110 Benchtop Fermentor

... a 4-baffle stainless-steel insert, dual Rushton agitation impellers, and a high-speed, direct-drive agitation system with mechanical face-seal. Dissolved ... . . . . . . . . . . . . . ... . 30% agitation . . . . . . . . . . . . . . . . . . . . 300 - ...

Rapamycin Optimized in 100 Liter Fermentor Using BioCommand Control Strategys

... a D.O. level of 30% of air saturation by automatically increasing agitation rates from 200 to 450 rpm, then vessel pressure from 0.35 to 0.75 bar, ... to be accomplished using a single loop control strategy ( see figure ). agitation rates could also be significantly reduced, to minimize shear forces and ...

Insect Cell Culture Using a BioFlo 110 Benchtop Bioreactor

... and other useful items. Optional direct drive and magnetic-drive agitation systems, as well as water-jacketed and heat-blanketed vessels are also ... DO . . . . . . . . . . . . . . . . . . . . . . . .50% agitation . . . . . . . . . . . . . . . . . . .70 - 130 rpm O 2 ...

Acrylamide Polymerization A Practical Approach

... for 15 min at room temperature (for systems in which constant agitation is used during degassing, 10 min is sufficient). Longer periods ... for 2 min at room temperature (for systems in which constant agitation is used for degassing, 1 min is sufficient). 2. Add ...

Double-Affinity Purification of GST-His Tagged Proteins Using Vivapure 8-to-96 Well Cobalt-Chelate Kit

... 500 ml LB medium. The cells were initially incubated at 37C under agitation (180 rpm) until the OD was 0.4, then at 20C. Protein expression was ... lysozyme 1mg/ml, DNase 1g/ml, 5 mM MgCl2), incubated for 30 min under agitation and the supernatant was recovered by centrifugation (3 min at 13,000 rpm). ...

140-Fold Increase of Protein Achieved in Pichia Fermentation

... oxygen (DO) during fermentation, (as well as a four-gas controller for use during cell culture). Using any of the systems four operating modes, agitation may be increased and/or pure oxygen added throughout the run to maintain the desired DO level. Second, the vessels stainless-steel ...

Fermentation Cell Culture: University Style

... the reproducibility and dynamic monitoring of variables such as dissolved oxygen, pH, temperature, and agitation speed allow us to predictably and reproducibly generate useful biomass for our experiments. BioPharm: ...

Gram Quantities of MAb Produced with Simple Bioreactor in Serum-Free Perfusion Culture Replacing Ascitic Fluid Production

... via the interactive pH-DO controller with CO 2 at the initial stage and then with an 8% NaHCO 3 solution when perfusion reached 2 volumes/day. agitation rate was initiated at 80 rpm and increased throughout the run to maintain the bottom DO concentration at > 35% air saturation. The maximal rate did ...

High Yield Protein Production from Pichia pastoris Yeast: A Protocol for Benchtop Fermentation

... which changes the speed of agitation. Pure oxygen was automatically supplied to the fermentor to keep the DO level at the setpoint after the agitation speed reached the maximum allowable setpoint. After the growth phase, a half-hour carbon-source starvation period was established before the ...

An Easy-to-Use Research Fermentor/Bioreactor

... system consists of a vessel, a Primary Control Unit for entering and displaying process parameters, and a Power Module to control temperature, agitation and pumps. Advanced Fermentation Kits include additional modules for pH/DO and foam/level control, as well as a pump module consisting ...

Transformation of Filamentous Fungi by High-Voltage Electroporation

... pH 5.8) containing Novozyme-234 (5 mg/ml) in a Petri dish; and, these plates were incubated at 28 C for 30 minutes with agitation in a rotary shaker at 150 rpm. The OSC generated with this treatment were then centrifuged in corex tubes at 4,000 x g for 5 minutes ...

Electrotransformation of E. coli With M13 DNA

... MgSO 4 2 ; pH 7.5) and then added to 1 liter SOB medium with 10 g/ml tetracycline. Bacteria were grown at 37 C with moderate agitation until they reached an O.D. 600 of approximately 0.3. Flasks were chilled on ice for 30 minutes, and cells were spun at 3,000 ...

Streptococcus salivarius

... 1. Cultivate cells by adding 1% overnight preculture to fresh medium. Grow cells at 37 C without agitation to a cell density of O.D. 660 of 0.5. Add glycine to a final concentration of 10% and incubate again for 1 h at 37 ...

Mycobacterium smegmatis

... 1. Grow cells in sidearm flask or tissue culture plates with gentle agitation until a Klett unit reading of 100 to 200 was obtained. 2. Harvest cells and wash three ...

Mycobacterium avium

... 1. Grow cells in sidearm flask or tissue culture plates with gentle agitation until a Klett unit reading of 100 to 200 was obtained. 2. Harvest cells and wash three ...

Streptococcus salivarius

... 1. Cultivate cells by adding 1% overnight preculture to fresh medium. Grow cells at 37 C without agitation to a cell density of O.D. 660 of 0.5. Add glycine to a final concentration of 10% and incubate again for 1 h at 37 ...

Mycobacterium smegmatis

... 1. Grow cells in sidearm flask or tissue culture plates with gentle agitation until a Klett unit reading of 100 to 200 was obtained. 2. Harvest cells and wash three ...

Mycobacterium avium

... 1. Grow cells in sidearm flask or tissue culture plates with gentle agitation until a Klett unit reading of 100 to 200 was obtained. 2. Harvest cells and wash three ...